Grail has launched its Galleri blood test, which is designed to detect multiple cancers early from a single sample, for prescription use in the US.
The company reported initial results from the interventional PATHFINDER study where the test demonstrated the ability to precisely identify 29 cancers across 13 types.
The test can be used for detecting individuals with an increased risk of cancer, including adults aged 50 or above, as well as to complement the present single cancer screening tests.
